> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# FDA Officials Detail Expanded Inspection Scrutiny of Combo Products
- URL: https://www.fdaweb.com/fda-officials-detail-expanded-inspection-scrutiny-of-combo-products/
- Published: 2026-11-21T02:05:00.000Z
- Updated: 2026-11-21T02:17:14.000Z
- Author: David McFarland
- Tags: Devices

FDA investigators will place greater emphasis on risk management, management oversight and supplier controls when inspecting drug-device combination product manufacturers under the agency's Quality Management System Regulation (QMSR), according to agency officials speaking at a regulatory conference this week.

As [reported by RAPS](https://www.raps.org/resource/fda-officials-detail-inspection-expectations-for-combination-products.html?ref=fdaweb.com), CDRH associate director for compliance and quality **Keisha Thomas** said manufacturers using the streamlined GMP approach under 21 CFR Part 4 should understand the revised requirements and inspection expectations.

The QMSR amendments align device-specific quality system provisions applicable to combination products with ISO 13485:2016, replacing references to the former Quality System Regulation. Affected products include prefilled syringes, drug-filled autoinjectors, drug-containing inhalers and drug-eluting devices.

Thomas emphasized that FDA expects senior management to take an active role in ensuring quality system compliance, rather than relying solely on established procedures and documentation.

FDA device inspection senior **Karen Masley-Joseph** said investigators will examine risk management documentation during every inspection and expect manufacturers to update those records throughout the product lifecycle. Investigators will also scrutinize purchasing controls and supplier oversight, with manufacturers expected to evaluate suppliers according to their individual risks.

In another significant change, Masley-Joseph said FDA investigators may now review internal audit reports, supplier audit reports and management review records. The previous Quality System Regulation generally excluded those records from routine FDA inspection review.

The officials spoke at the AFDO/RAPS Healthcare Products Collaborative Combination Products Summit in Baltimore.